SNY - Sanofi
About Sanofi (https://www.sanofi.com)
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Belen Garijo Lopez | Chief Executive Officer & Director | 1960 | $4,724,298 EUR |
| Emmanuel Frenehard | Executive VP & Chief Digital Officer | 1972 | – |
| Erik Wallström | Head of Therapeutic Area - Neurology Development | – | – |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | – | – |
| François-Xavier Roger | Executive Vice President & Chief Financial Officer | 1962 | – |
| Houman Ashrafian | Executive VP & Head of Research & Development | 1975 | – |
| Jamie Haney | Executive Vice President & General Counsel | – | – |
| Karin Knobe | TA Head of Rare Diseases & Rare Blood Disorders Development | – | – |
| Madeleine Roach | Executive Vice President & Head of Business Operations | 1984 | – |
| Michael Quigley | Chief Scientific Officer & Head of Research | – | – |
| Olivier Charmeil | Executive Vice President of General Medicines | 1963 | – |
| Olivier Klaric | Senior Vice President of Financing & Treasury | 1962 | – |
| Pablo Sardi | TA Head of Rare & Neurologic Diseases Research | – | – |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 1957 | – |
| Roy Papatheodorou | Executive Vice President & General Counsel | 1978 | – |
| Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 1974 | – |
| Thomas Triomphe | Executive Vice President of Vaccines | 1974 | – |
| Veronique Jaillet | Executive VP & Interim Chief People Officer | – | – |